Blessing for QUB cystic fibrosis treatment
A groundbreaking treatment for cystic fibrosis (CF) pioneered by Queen's University experts has been given EU approval.
In a step that could hugely improve patients' quality of life, researchers trialled a combination of two drugs, Lumafactor and Ivacaftor, and found the approach could improve lung function by bypassing the genetic errors that cause the disease.
The Cystic Fibrosis Trust said the approach, which is effective on sufferers with a genetic make-up including two copies of the F508del gene mutation, could "open up a new front in the fight against cystic fibrosis", which affects one in every 2,500 babies born in the UK.
Queen's University's Professor Stuart Elborn, who co-authored the study with colleagues from the US and Australia, added the technique produced real effects.
"The combination represents a step-change in the management of CF for these patients because it addresses the underlying cause of the disease. By doing so, it has shown meaningful, sustained benefits," he said.